Antiplatelet therapy (first of two parts).
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects; D002994:Clofibrate / Q000494:pharmacology; D003911:Dextrans / Q000494:pharmacology; D004176:Dipyridamole / Q000494:pharmacology / Q000627:therapeutic use; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D010973:Platelet Adhesiveness / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use; D011817:Rabbits; D013442:Sulfinpyrazone / Q000494:pharmacology; D013927:Thrombosis / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D003911:Dextrans; D004176:Dipyridamole; D006493:Heparin; D011433:Propranolol; D002994:Clofibrate; D001241:Aspirin; D013442:Sulfinpyrazone